ANTX · ISSUER CIK 1880438
AN2 Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 8 AN2 Therapeutics, Inc. insiders reported $12K of open-market purchases and $318K of sales on SEC Form 4. The largest buyer was FitzPatrick Margaret M (Director), with $12K.
↗8 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 3 of 4 sales were reported under a 10b5-1 plan.
$12KInsider buying
$318KInsider selling
−$307KNet open-market
Oct 13, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 13, 202617:13 | Oct 12, 2026 | ANTX | Director | A · Grant | — | +2,283 | 84,156 | +3% | — | ||
| Oct 13, 202617:12 | Oct 12, 2026 | ANTX | Director | A · Grant | — | +389 | 19,252 | +2% | — | ||
| Oct 13, 202617:12 | Oct 12, 2026 | ANTX | Director | A · Grant | — | +2,465 | 61,571 | +4% | — | ||
| Sep 16, 202617:35 | Sep 15, 2026 | ANTX | Chief Medical Officer | A · Grant | — | +116,667 | 116,667 | New | — | ||
| Sep 11, 202619:45 | Sep 9, 2026 | ANTX | Director | S · Sell10b5-1 | $6.02 | −1,108 | 624,765 | -0% | −$7K | ||
| Sep 8, 202619:42 | Sep 8, 2026from Sep 3, 2026 | ANTX | Director | S · Sell10b5-1 | $6.04 | −16,119 | 625,350 | -3% | −$97K | ||
| Sep 4, 202616:25 | Sep 1, 2026 | ANTX | Principal Accounting Officer | S · Sell | $5.53 | −272 | 66,311 | -0% | −$2K | ||
| Sep 2, 202618:43 | Sep 1, 2026 | ANTX | Director | P · Buy | $5.53 | +2,098 | 10,708 | +24% | +$12K | -11.9% | -15.2% |
| Aug 19, 202617:58 | Aug 17, 2026 | ANTX | Director | S · Sell10b5-1 | $6.01 | −35,402 | 633,867 | -5% | −$213K | ||
| Aug 14, 202614:12 | Aug 14, 2026 | ANTX | Director | G · Gift | — | −405,880 | 0 | -100% | — |